NovoCure (NVCR) Cash from Operations Growth (3y) (2017 - 2026)
NovoCure (NVCR) Cash from Operations Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -48.14% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 50.11% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -14.75% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 0.50% |
| 10 | NovoCure | 1.97 Bn | 1.53 Bn | 142.48 Mn | 33.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.09% |
| Mar 31, 2026 | 6.86% |
| Dec 31, 2025 | -69.35% |
| Sep 30, 2025 | -2.82% |
| Jun 30, 2025 | -44.40% |
| Mar 31, 2025 | -113.07% |
| Dec 31, 2024 | -30.83% |
| Sep 30, 2024 | -24.80% |
| Jun 30, 2024 | -27.36% |
| Mar 31, 2024 | -55.72% |
| Dec 31, 2023 | -31.47% |
| Sep 30, 2023 | -37.92% |
| Jun 30, 2023 | -55.84% |
| Mar 31, 2023 | -119.30% |
| Dec 31, 2022 | -36.31% |
| Sep 30, 2022 | 14.57% |
| Jun 30, 2022 | 20.24% |
| Mar 31, 2022 | 5.11% |
| Dec 31, 2021 | -5.03% |
| Sep 30, 2021 | 62.96% |